Angiotensin II (AT-II)-Receptor Antagonists are Reviewed. Research focused on blocking the renin- angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors ...

The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium. Arbli, an angiotensin II receptor blocker, is indicated for the treatment of ...

Discover how this crimson brew may lower blood pressure as effectively as medication while offering additional heart health ...

Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...

Arbli, an angiotensin II receptor blocker, is indicated for the treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old; for the reduction of the risk of ...

NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGSIf approved, FILSPARI could become the first and ...

Travere Therapeutics (TVTX) has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking priority review ...

NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney ...

Healthy snacking is the order of the day, and Makhanas tops the list among those looking to lose weight. However, according to experts, makhanas, or fox nuts, should not be overconsumed as they not ...

StockNews.com upgraded shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) from a sell rating to a hold rating in a ...

Special Report: Dimerix has received the initial payment of ¥300 million (A$3.2 million) in line with its recently announced licence agreement with Japanese FUSO Pharmaceutical Industries Ltd in Japan ...